HOW CAN YOU ACCESS THE LATEST CLL TREATMENT OPTIONS?

The Pro-Active CLL Patient Toolkit

PHASES OF A CLINICAL TRIAL

- **Phase I**: The goal is to test the safety of the drug, finding the appropriate dose that produces the fewest side effects.
- **Phase II**: Further assesses the safety of the drug. The drug is tested on more humans with a specific disease.
- **Phase III**: Compares the efficacy of a new drug to the standard-of-care treatment. Usually a randomized clinical trial with enrollment of 100 or more patients.

TARGETED CLL TREATMENT OPTIONS

Approved Inhibitor Treatments for CLL:

- BTK inhibitors
  - Acalabrutinib (Calquence)
  - Ibrutinib (Imbruvica)
- PI3K inhibitors
  - Duvelisib (Copiktra)
  - Idelalisib (Zydelig)
- BCL-2 inhibitor
  - Venetoclax (Venclexta)

Approved Monoclonal Antibody Treatments for CLL:

- Alemtuzumab (Campath)
- Obinutuzumab (Gazyva)
- Ofatumumab (Arzerra)
- Rituximab (Rituxan)

View [How Can You Access the Latest CLL Treatment Options?](#) here.

GLOSSARY OF TERMS

**Chimeric Antigen Receptor (CAR) T-cell therapy**: An immunotherapy that is currently being studied to treat CLL.

**IGHV Mutation**: CLL patients with mutated IGHV may have a longer time to treatment and can have different responses and duration of responses specific to chemotherapy.

**Minimal Residual Disease (MRD)**: Refers to the small number of cancer cells that remain in the body after treatment.